Morningstar - Exelon Corporation (EXC) Exelon Moves Its Focus Toward Attaining Pennsylvania Support for its Nuclear Fleet

Report

Morningstar

Andrew Bischof

EUR 100.00 For Business Accounts Only

Exelon Moves Its Focus Toward Attaining Pennsylvania Support for its Nuclear Fleet

We are reaffirming our $43 fair value estimate and our narrow moat and stable moat trend ratings for Exelon after the company announced adjusted first-quarter earnings per share of $0.87, down from $0.96 in the same year-ago period. Management reaffirmed 2019 EPS guidance range of $3.00-$3.30, consistent with our full-year expectation.
Exelon has a strong track record of lobbying and securing support for its economically challenged nuclear fleet. In New Jersey, the Board of Public Utilities vote...

03/05/2019 13 EN

Underlying

Exelon Corporation

Exelon is a utility services holding company engaged in the generation, delivery and marketing of energy through Exelon Generation Company, LLC and the energy distribution and transmission businesses through Commonwealth Edison Company, PECO Energy Company, Baltimore Gas and Electric Company, Potomac Electric Power Company, Delmarva Power & Light Company and Atlantic City Electric Company. Through its business services subsidiary Exelon Business Services Company, LLC, the company provides its subsidiaries with a variety of support services.

See profile

US30161N1019 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Andrew Bischof

Other Reports on these Companies

BusinessWire

Exelon Appoints David DeWalt to Board of Directors

CHICAGO--(BUSINESS WIRE)-- Exelon (Nasdaq: EXC) today announced the appointment of David DeWalt, founder and chief executive officer of cybersecurity and venture capital firm NightDragon, to its Board of Directors effective March 10, 2025. This press release features multimedia. View the full release here: David DeWalt, founder and chief executive officer of cybersecurity and venture capital firm NightDragon. (Photo: Business Wire) DeWalt, 60, is a global authority on technology, security and safety, and he helmed cybersecurity industry leaders FireEye, Inc., and McAfee, Inc., before founding ...

March 10, 2025 March 10, 2025 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Testing Initial Support In last week's 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, and that if the S&P 500 remains below 6100 and 6150 resistances, do not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers (though we need 5600 support to hold in order to remain constructive). The S&P 500 and Nasdaq 100 (QQQ) are testing m...

EUR 42.77

March 4, 2025 March 4, 2025 1 EN

BusinessWire

Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook

CHICAGO--(BUSINESS WIRE)-- Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024. "I am pleased to announce Exelon has delivered against our financial goals for the third straight year since becoming a transmission and delivery-only company, and we delivered top quartile performance across all our local energy companies, with ComEd and Pepco Holdings in the top decile," said Exelon President and Chief Executive Officer Calvin Butler. "Our commitment to our customers, grid reliability, community investment and being an economic engine ...

February 12, 2025 February 12, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Exelon Moves Its Focus Toward Attaining Pennsylvania Support for its Nuclear Fleet

Exelon Appoints David DeWalt to Board of Directors

Vermilion Compass: Weekly Equity Strategy

Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe